BridgeMD
New treatment option for Endometrial Cancer
Official title Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer
ClinicalTrials.gov ID: NCT07116213
What this study is testing
- What it's testing
- 1. Study Type: Single-center, single-arm, prospective study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70, women only
You may be able to join if
- Age : 18-70 years old.
- Performance Status : ECOG score 0-2.
- Expected to comply with oART (Online Adaptive Radiotherapy) workflow.
- Initial Surgical Treatment : Total hysterectomy and bilateral salpingo-oophorectomy ± Pelvic and/or para-aortic lymph node dissection/sampling or...
- Pathological Staging \& Histology (per FIGO 2009): Stage I : Grade 3 endometrioid adenocarcinoma with superficial myometrial invasion and extensive...
You likely can't join if
- Prior Radiotherapy : History of abdominal or pelvic irradiation.
- Treatment Interval : Without adjuvant chemotherapy: \>12 weeks between surgery and radiotherapy initiation. With adjuvant chemotherapy: \>6 months...
- Malignancy History : Prior diagnosis of other malignancies.
- Pregnancy/Lactation : Pregnant or breastfeeding women.
- Active Infection : Fever or uncontrolled active infection.
- Inflammatory Bowel Disease (IBD) : History of IBD (regardless of activity status).
See the full eligibility criteria
- Age : 18-70 years old.
- Performance Status : ECOG score 0-2.
- Expected to comply with oART (Online Adaptive Radiotherapy) workflow.
- Initial Surgical Treatment : Total hysterectomy and bilateral salpingo-oophorectomy ± Pelvic and/or para-aortic lymph node dissection/sampling or sentinel lymph node biopsy.
- Pathological Staging \& Histology (per FIGO 2009): Stage I : Grade 3 endometrioid adenocarcinoma with superficial myometrial invasion and extensive LVSI (Lymphovascular Space Invasion). Grade 2 endometrioid...
- Informed Consent :
- Patients and families fully understand the study protocol.
- Voluntarily participate and sign informed consent forms before enrollment
- Prior Radiotherapy : History of abdominal or pelvic irradiation.
- Treatment Interval : Without adjuvant chemotherapy: \>12 weeks between surgery and radiotherapy initiation. With adjuvant chemotherapy: \>6 months between surgery and radiotherapy initiation.
- Malignancy History : Prior diagnosis of other malignancies.
- Pregnancy/Lactation : Pregnant or breastfeeding women.
- Active Infection : Fever or uncontrolled active infection.
- Inflammatory Bowel Disease (IBD) : History of IBD (regardless of activity status).
- Comorbidities : Severe conditions affecting trial compliance, including: Unstable cardiac disease requiring treatment, renal impairment, chronic hepatitis, poorly controlled diabetes, psychiatric disorders
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.